These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38902152)

  • 21. Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study.
    Morata Ruiz L; Ruggieri A; Falcone M; Pasquau Liaño J; Gentile I; Salavert Lletí M; Moreno Núñez L; Cascio A; Tascini C; Loeches Yagüe M; De Rosa FG; Ori A; Comandini A; Cattaneo A; Grossi PA;
    J Glob Antimicrob Resist; 2024 Mar; 36():200-209. PubMed ID: 38211660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections.
    Gallerani A; Gatti M; Bedini A; Casolari S; Orlando G; Puzzolante C; Franceschini E; Menozzi M; Santoro A; Barp N; Volpi S; Soffritti A; Pea F; Mussini C; Meschiari M
    Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
    Steele JM; Seabury RW; Hale CM; Mogle BT
    J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety.
    Ruiz-Sancho A; Núñez-Núñez M; Castelo-Corral L; Martínez-Marcos FJ; Lois-Martínez N; Abdul-Aziz MH; Vinuesa-García D
    Front Pharmacol; 2023; 14():1185602. PubMed ID: 37448966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profile of Infective Endocarditis: At a Tertiary Care Referral Centre.
    R M; V R; Nambi PS; Ramakrishnan B; Gopalakrishnan R; Sathyamurthy
    J Assoc Physicians India; 2018 Jun; 66(6):60-65. PubMed ID: 31331138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort study.
    Krsak M; Scherger S; Miller MA; Cobb V; Montague BT; Henao-Martínez AF; Molina KC
    Ther Adv Infect Dis; 2024; 11():20499361231223889. PubMed ID: 38249543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care.
    Ajaka L; Heil E; Schmalzle S
    Antibiotics (Basel); 2020 Oct; 9(10):. PubMed ID: 33076275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term Oral Suppressive Antimicrobial Therapy in Infective Endocarditis (SATIE Study): An Observational Study.
    Beaumont AL; Mestre F; Decaux S; Bertin C; Duval X; Iung B; Rouzet F; Grall N; Para M; Thy M; Deconinck L
    Open Forum Infect Dis; 2024 May; 11(5):ofae194. PubMed ID: 38737431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infective endocarditis in Rio de Janeiro, Brazil: a 5-year experience at two teaching hospitals.
    Damasco PV; Ramos JN; Correal JC; Potsch MV; Vieira VV; Camello TC; Pereira MP; Marques VD; Santos KR; Marques EA; Castier MB; Hirata R; Mattos-Guaraldi AL; Fortes CQ
    Infection; 2014 Oct; 42(5):835-42. PubMed ID: 24934541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.
    Matt M; Duran C; Courjon J; Lotte R; Moing VL; Monnin B; Pavese P; Chavanet P; Khatchatourian L; Tattevin P; Cattoir V; Lechiche C; Illes G; Lacassin-Beller F; Senneville E; Dinh A;
    J Glob Antimicrob Resist; 2021 Jun; 25():341-345. PubMed ID: 33962065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
    Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
    J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oritavancin as sequential therapy for Gram-positive bloodstream infections.
    Texidor WM; Miller MA; Molina KC; Krsak M; Calvert B; Hart C; Storer M; Fish DN
    BMC Infect Dis; 2024 Jan; 24(1):127. PubMed ID: 38267844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness, safety and cost analysis of dalbavancin in clinical practice.
    Arrieta-Loitegui M; Caro-Teller JM; Ortiz-Pérez S; López-Medrano F; San Juan-Garrido R; Ferrari-Piquero JM
    Eur J Hosp Pharm; 2022 Jan; 29(1):55-58. PubMed ID: 33020060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal Changes, Patient Characteristics, and Mortality, According to Microbiological Cause of Infective Endocarditis: A Nationwide Study.
    Østergaard L; Voldstedlund M; Bruun NE; Bundgaard H; Iversen K; Køber N; Christensen JJ; Rosenvinge FS; Jarløv JO; Moser C; Andersen CØ; Coia J; Marmolin ES; Søgaard KK; Lemming L; Køber L; Fosbøl EL
    J Am Heart Assoc; 2022 Aug; 11(16):e025801. PubMed ID: 35946455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality.
    de Pablo-Miró M; Pujol-Ruiz S; Iftimie S; Arenas-Miras MDM; López-Montesinos I; Duran-Jordà X; Anglès A; Grau S; Horcajada JP
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prevalence of persistent bacteraemia in patients with a non-staphylococcal infective endocarditis, a retrospective cohort study.
    van der Vaart TW; Stuifzand M; Boekholdt SM; Cramer MJ; Bonten MJM; Prins JM; van der Meer JTM
    Int J Cardiol; 2022 Nov; 367():49-54. PubMed ID: 36002040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The current and future off-label uses of dalbavancin: a narrative review.
    De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.